Apotex-Strides tie-up is cleared by ACCC
Australia’s Competition and Consumer Commission (ACCC) has approved Apotex and Strides Pharma Science’s agreement to merge their Australian businesses, deciding that the transaction “will not substantially lessen competition in any market”.
You may also be interested in...
Strides Pharma Science has agreed to sell its entire Australian business, including its local Arrow unit, to the Arrow-Apotex merged entity known as ‘Arrotex’, as the firm concentrates its efforts in the US and Canada.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.